Stock Performance and Market Context
The stock of Gujarat Kidney & Super Speciality Ltd, a micro-cap player in the hospital industry, has demonstrated strong momentum, outperforming its sector and the broader market indices. On the day it hit the all-time high, the share price rose by 0.87%, contrasting with the Sensex’s decline of 0.24%. Over the past week, the stock surged by 9.77% while the Sensex fell by 0.81%, and over the last month, it gained an impressive 29.58% compared to the Sensex’s 2.76% decline.
Extending the horizon, the stock has delivered a 32.94% return over three months, significantly outpacing the Sensex’s modest 2.81% gain. Year-to-date, Gujarat Kidney & Super Speciality Ltd has surged by 69.49%, while the Sensex has declined by 10.43%. This strong relative performance underscores the stock’s bullish trend and investor confidence in its recent trajectory.
Technical Indicators and Trend Analysis
The technical outlook for Gujarat Kidney & Super Speciality Ltd remains firmly bullish. The stock is trading above all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, signalling sustained upward momentum. The current trend shifted to bullish on 04 Sep 2026 at a price of Rs.172.65, reinforcing the positive technical sentiment.
Key technical indicators such as MACD, Bollinger Bands, Dow Theory, and On-Balance Volume (OBV) support the bullish stance on both weekly and monthly timeframes. Although the Relative Strength Index (RSI) shows a bearish signal, the overall technical trend remains positive, with immediate support at Rs.98.25 (52-week low) and resistance levels at Rs.152.50 (20-day moving average) and Rs.176 (52-week high).
Financial Performance Driving the Rally
The company’s recent financial results have been a major contributor to the stock’s upward movement. Gujarat Kidney & Super Speciality Ltd reported its highest quarterly net sales at Rs.34.29 crores, accompanied by a 23.1% growth in profit before tax excluding other income, reaching Rs.6.27 crores. The quarterly profit after tax also hit a record Rs.5.18 crores, reflecting strong operational efficiency and profitability.
These results mark the second consecutive quarter of positive earnings growth, with operating profit increasing by 80.69% in the latest quarter. Such robust financial metrics have underpinned the company’s upgrade in rating from Hold to Buy by MarketsMOJO on 04 Sep 2026, supported by a Mojo Score of 70.0.
Quality and Valuation Metrics
Gujarat Kidney & Super Speciality Ltd exhibits a strong quality profile with excellent growth and capital structure grades. The company maintains a low debt-to-EBITDA ratio of 1.08 times, indicating a healthy ability to service debt. Its average return on capital employed (ROCE) stands at a strong 26.45%, while management risk is assessed as average.
However, valuation metrics suggest a premium pricing environment. The stock trades at a price-to-earnings (P/E) ratio of 86 times trailing twelve months earnings and a price-to-book value of 5.40 times, reflecting a very expensive valuation. Enterprise value multiples such as EV/EBITDA at 49.62x and EV/EBIT at 60.11x further highlight the elevated valuation levels.
Market Capitalisation and Institutional Holdings
Despite its recent price surge, Gujarat Kidney & Super Speciality Ltd remains a micro-cap company. Institutional participation is limited, with domestic mutual funds holding a negligible stake of 0%, which may reflect cautious positioning given the stock’s valuation and size. The company has no promoter share pledging, and institutional holdings overall stand at a modest 5.44%.
Delivery Volumes and Trading Activity
Trading activity has intensified alongside the price rally. Delivery volumes over the past month have increased by 155.49%, with a notable 81.1% rise in delivery volume on the day of the all-time high compared to the five-day average. This heightened trading interest supports the sustained price appreciation observed in recent sessions.
Historical Performance Comparison
While the stock has delivered no return over the past year, its profits have risen by 65%, indicating improving operational results despite flat price movement in that period. Over longer horizons, the stock’s performance data is not available, but the Sensex benchmark has delivered returns of 15.19% over three years, 30.98% over five years, and 163.88% over ten years, providing context for the company’s market standing.
Summary of Key Financial and Market Metrics
• All-time high price: Rs.176 on 07 Sep 2026
• Market cap: Micro-cap classification
• Mojo Grade: Buy (upgraded from Hold on 04 Sep 2026)
• Debt to EBITDA: 1.08 times (low leverage)
• Quarterly net sales: Rs.34.29 crores (highest)
• Quarterly PAT: Rs.5.18 crores (highest)
• P/E Ratio (TTM): 86x
• Price to Book Value: 5.40x
• ROCE: 26.45% (strong)
• Institutional holdings: 5.44%
• Delivery volume increase (1 month): 155.49%
Conclusion
Gujarat Kidney & Super Speciality Ltd’s achievement of an all-time high price of Rs.176 is a testament to its recent financial strength and positive market momentum. Supported by strong quarterly results, a bullish technical trend, and a solid quality profile, the stock has outperformed its sector and the broader market indices significantly over multiple timeframes. While valuation levels remain elevated, the company’s ability to sustain growth and maintain a healthy balance sheet has been clearly demonstrated in its recent performance.
